Gastrointestinal Cancers and Clinical Trials: What Patients Need to Know Earlier On - Top-Institutions - MDSpire

Gastrointestinal Cancers and Clinical Trials: What Patients Need to Know Earlier On

Breakthrough treatments for gastrointestinal cancers are being tested in clinical trials right now.

  • By

  • May 20, 2026

  • 9 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    USC Norris Comprehensive Cancer Center
    USC Norris Comprehensive Cancer Center

    Los Angeles, CA

    Key Differentiators

    • Oncology

  • #2

    Keck Medicine of USC
    Keck Medicine of USC

    Los Angeles, CA

    Key Differentiators

    • Oncology

  • #3

    The Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute
    The Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute

    Columbus, OH

    Key Differentiators

    • Oncology

  • #4

    Duke University School of Medicine
    Duke University School of Medicine

    Durham, NC

    Key Differentiators

    • Oncology

  • #5

    National Cancer Institute
    National Cancer Institute

    Bethesda, MD

    Key Differentiators

    • Oncology

Original Source(s)

Gastrointestinal Cancers and Clinical Trials: What Patients Need to Know Earlier On

  • by

  • May 20, 2026

Related Content

Turning Medical Insights into Patient Impact

Veeva research reveals a stark gap between the insights biopharma captures and the actions it takes – highlighting a missed opportunity to improve patient outcomes

Rethinking Progress in Clinical Trials

Three clinical development leaders discuss how early signals, trial design, regulatory expectations, and patient access are reshaping clinical development

  • May 20, 2026

  • 11 min
Roswell Park Experts Report on Discovery of Rare Bladder Cells, Neural Mapping of Pelvic Floor Muscles at AUA 2026

Evidence provided by a Roswell Park study indicates that neoadjuvant chemotherapy may be the preferred course of treatment for patients with non-muscle-invasive bladder cancer (NMIBC) when their disease progresses and they are diagnosed with muscle-invasive bladder cancer (MIBC)

  • by

  • May 19, 2026

  • 7 min